about
Targeting folate receptor alpha for cancer treatmentCharacterization of H type 1 and type 1 N-acetyllactosamine glycan epitopes on ovarian cancer specifically recognized by the anti-glycan monoclonal antibody mAb-A4.CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian CancerClinical and Survival Impact of FDG PET in Patients with Suspicion of Recurrent Ovarian Cancer: A 6-Year Follow-Up.Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancerREG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.Production and Characterization of a Novel Monoclonal Antibody Against Human SortilinRole of NSC319726 in ovarian cancer based on the bioinformatics analysesThe status of epidermal growth factor receptor in borderline ovarian tumours.Therapeutic targets and new directions for antibodies developed for ovarian cancer.The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.Ellagic Acid and Resveratrol Prevent the Development of Cisplatin Resistance in the Epithelial Ovarian Cancer Cell Line A2780.An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.Apoptotic Effect of Sanggenol L via Caspase Activation and Inhibition of NF-κB Signaling in Ovarian Cancer Cells.Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.Specific immunotherapy in ovarian cancer: a systematic review.Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.Nanoceria-mediated delivery of doxorubicin enhances the anti-tumour efficiency in ovarian cancer cells via apoptosis.Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells.Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients.Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.KPNA2 is a potential diagnostic serum biomarker for epithelial ovarian cancer and correlates with poor prognosis.Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis.Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer.Effect of nisin and doxorubicin on DMBA-induced skin carcinogenesis--a possible adjunct therapy.Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche.A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer
P2860
Q26744215-F5238DA7-2A85-4E70-9633-B26B4820DF7BQ33564920-2D823E66-B1A8-4BB4-BA8F-C8C223EE8684Q35790380-9D3AC82D-4004-4305-8493-483FDCD8CE99Q35877090-E927C877-E3E5-4A65-9180-79E2ABB12D20Q35958147-0DD24236-FF14-44FE-BE7B-5560ED019BB1Q35959074-85CB2855-C7E5-4C12-A8BE-B444EE886813Q36388428-DEA6DC76-398B-4E21-B9D7-1C2CA876E104Q36399060-F1263A02-1B55-4825-BFAF-194801B02D99Q36963030-2FE4A265-6278-4256-826E-331BA6B4ECF7Q37397674-6224AE12-C549-46CC-8FB2-9D149110C42CQ37631697-6CFA1EE8-4E6D-4ABD-894E-81D291E672F8Q37696086-D6CEC02A-682D-4619-959D-66FD8E683E85Q38355123-92DBA58C-7AC0-44A7-8D5E-BA6F5A3BA75AQ38631373-ED3C29EF-4BA2-4E39-8211-E4AAE8B317E1Q38726540-208CB1AD-94E3-4456-B289-D8AB74A8E612Q38820413-C35774EA-C1FE-4CE3-BCCF-0EEC1859733DQ38848614-02C5155A-B71F-44D1-A25F-051A0C1B1DA5Q38948893-2D1784ED-278E-45DD-8565-D290BA6234A0Q38996872-3CB65A36-9526-4671-B0B0-93D4C5E5DE8EQ41529535-3C2C1E1E-807D-42A3-AC29-9F7313037F3FQ45070718-3821C2C5-0EFA-4E22-B0C9-C68C98D5DFEFQ47137229-89CF923D-397D-4D37-933B-64E80BBFFD7BQ47965726-36118C8A-1A3C-4B85-AB7F-C0E6900E2F7CQ48131479-CFFF1DCD-3B70-483C-A51D-FD3D5E8F8CE0Q48628148-E9FA5DB8-3AD7-47C2-BD2C-9C888994FCB6Q49788115-12C2C574-2C54-4522-8B12-2316E3E2EC07Q50420907-2C5567C4-68DF-44E5-924C-8F4FBADF0547Q53218890-D36371B4-D437-4C8B-8131-6425C54DE19BQ54979642-0D9E8139-326F-4857-94D9-B3F4D6A546EBQ55257164-292432D8-BF50-498F-8DE6-242C995D82E2Q57298278-BE0EF46E-D432-422E-AE4F-46E701178CB3
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
New perspectives on targeted therapy in ovarian cancer
@ast
New perspectives on targeted therapy in ovarian cancer
@en
New perspectives on targeted therapy in ovarian cancer
@nl
type
label
New perspectives on targeted therapy in ovarian cancer
@ast
New perspectives on targeted therapy in ovarian cancer
@en
New perspectives on targeted therapy in ovarian cancer
@nl
prefLabel
New perspectives on targeted therapy in ovarian cancer
@ast
New perspectives on targeted therapy in ovarian cancer
@en
New perspectives on targeted therapy in ovarian cancer
@nl
P2860
P3181
P356
P1476
New perspectives on targeted therapy in ovarian cancer
@en
P2093
Kathryn Middleton
P2860
P304
P3181
P356
10.2147/IJWH.S52379
P407
P577
2015-02-04T00:00:00Z